Chronic kidney disease: Are elevated doses of ESAs associated with adverse outcomes?

Nature Reviews Nephrology

Volumn 6, Issue 10, 2010, Pages 566-568

  Eckardt, Kai Uwe ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; DIABETES MELLITUS; DRUG DOSE COMPARISON; HAZARD RATIO; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MORTALITY; POLICY; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; STROKE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANEMIA; CHRONIC DISEASE; HEMATINICS; HUMANS; KIDNEY DISEASES; RISK FACTORS; TREATMENT OUTCOME;

EID: 77957607377     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.115     Document Type: Short Survey

References (9)

1. Brookhart, M. A. et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 303, 857-864 (2010).
2. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009).
3. Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584-590 (1998).
4. Drüeke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071-2084 (2006).
5. Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006).
6. Volkova, N. & Arab, L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am. J. Kidney Dis. 47, 24-36 (2006).
7. Kilpatrick, R. D. et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 1077-1083 (2008).
8. Szczech, L. A. et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 74, 791-798 (2008).
9. Unger, E. F., Thompson, A. M., Blank, M. J. & Temple, R. Erythropoiesis stimulating agents-time for a reevaluation. N. Engl. J. Med. 362, 189-192 (2010).